A Master Protocol for Biomarker-Based Treatment of AML (The Beat AML Trial)

Trial Profile

A Master Protocol for Biomarker-Based Treatment of AML (The Beat AML Trial)

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 04 Apr 2017

At a glance

  • Drugs Samalizumab (Primary) ; Enasidenib; Entospletinib
  • Indications Acute myeloid leukaemia
  • Focus Therapeutic Use
  • Acronyms BEAT AML Master Trial
  • Most Recent Events

    • 16 Feb 2017 According to Alexion Pharmaceuticals media release, patients are being dosed in this trial.
    • 13 Dec 2016 According to Alexion Pharmaceuticals' website, the Leukemia and Lymphoma Society is conducting this trial.
    • 13 Dec 2016 Status changed from planning to recruiting, based on the information present in Alexion Pharmaceuticals website.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top